Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3/CD141+ dendritic cells and enhanced cross-presentation

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 495-505

  Sluijter, Berbel J R ^a   Van Den Hout, Mari F C M ^a   Koster, Bas D ^a   Van Leeuwen, Paul A M ^a   Schneiders, Famke L ^a   Van De Ven, Rieneke ^a   Molenkamp, Barbara G ^a   Vosslamber, Saskia ^a   Verweij, Cornelis L ^a   Van Den Tol, M Petrousjka ^a   Van Den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; BLOOD DENDRITIC CELL ANTIGEN 3, HUMAN; CYTOKINE; MEMBRANE ANTIGEN; OLIGODEOXYRIBONUCLEOTIDE;

ADULT; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVATION; CELL MATURATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; EX VIVO STUDY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; IN VIVO STUDY; INJECTION SITE INDURATION; INJECTION SITE REACTION; MALE; MELANOMA; MYALGIA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIMARY TUMOR; SENTINEL LYMPH NODE METASTASIS; TUMOR IMMUNITY; AGED; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; LYMPH NODE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; ANTIGENS, SURFACE; CELLS, CULTURED; CROSS-PRIMING; CYTOKINES; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; SENTINEL LYMPH NODE BIOPSY;

EID: 84962216970     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0165     Document Type: Article

References (50)

1. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001;14:604-8.
2. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005; 11:107-12.
3. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007;13:2961-9.
4. + T cell reactivity in melanoma patients. Clin Cancer Res 2008;14:4532-42.
5. + T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 2006;12: 2826-33.
6. Wang W, Edington HD, Rao UNM, Jukic DM, Radfar A, Wang H, et al. Effects of high-dose IFN alpha 2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008;14:8314-20.
7. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28:4324-32.
8. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119:355-63.
9. Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010;184:4276-83.
10. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007;178:1534-41.
11. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61:195-204.
12. Patterson S. Flexibility and cooperation among dendritic cells. Nat Immunol 2000;1:273-4.
13. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK-and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247-53.
14. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 2002;32:2617-22.
15. Nierkens S, denBrok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, et al. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 2011;71:6428-37.
16. Vuylsteke RJCLM, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands PGJTB, Vos W, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 2004;64:8456-60.
17. Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003;63:394-9.
18. Tarhini AA, Leng SY, Moschos SJ, Yin Y, Sander C, Lin Y, et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 2012;35:359-66.
19. van deVen R, van den Hout MF, Lindenberg JJ, Sluijter BJ, van Leeuwen PA, Lougheed SM, et al. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood 2011;118:2502-10.
20. Segura E, Valladeau-Guilemond J, Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 2012;209:653-60.
21. Nestle FO, Nickoloff BJ. Deepening our understanding of immune sentinels in the skin. J Clin Invest 2007;117:2382-5.
22. Santegoets SJAM, Bontkes HJ, Stam AGM, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJM, et al. Inducing antitumor Tcell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J Immunol 2008;180:4540-9.
23. + dendritic cells. JE xp Med 2010;207:1273-81.
24. Veen Hvd, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769-70.
25. Vuylsteke RJCLM, van Leeuwen PAM, Meijer S, Wijnands PGJTB, Statius Muller MG, Busch DH, et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 2002;161:19-26.
26. Elliott B, Cook MG, John RJ, Powell BW, Pandha H, Dalgleish AG. Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods 2004;291:71-8.
27. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008;14:5884-92.
28. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11.
29. Schneiders FL, de Bruin RCG, Santegoets SJAM, Bonneville M, Scotet E, Scheper RJ, et al. Activated iNKT cells promote V gamma 9V delta 2-T cell anti-tumor effector functions through the production of TNF-alpha. Clin Immunol 2012;142:194-200.
30. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol 2005;167:1301-7.
31. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247-60.
32. + dendritic cells. J Exp Med 2010;207: 1261-71.
33. Schakel K, von KM, Hansel A, Ebling A, Schulze L, Haase M, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006;24: 767-77.
34. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010;9:519-25.
35. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46.
36. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999;96:9305-10.
37. la Bella S, Nicola S, Riva A, Biasin M, Clerici M, Villa ML. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J Leukoc Biol 2004;75:106-16.
38. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, et al. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol 2009;39:56-66.
39. Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expres-sing dendritic cells with potent functional activities. J Immunol 2003;171:3385-93.
40. Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008;31:254-62.
41. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, et al. IFN-alpha-conditioneddendritic cells are highly efficient ininducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 2006;36:2046-60.
42. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, et al. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012; 119:1407-17.
43. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
44. + nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha. J Immunol 2008;181:2999-3008.
45. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008;9:R17.
46. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012;36: 635-45.
47. de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J. CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8 alpha(+) dendritic dells. J Immunol 2011;186:1503-11.
48. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013;210:1035-47.
49. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 2006;7:740-6.
50. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007;109:5371-9.